- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02726256
G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)
15. april 2016 oppdatert av: Yonsei University
The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications.
Diabetes develops due to glucose intolerance.
Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications.
This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.
Studieoversikt
Status
Har ikke rekruttert ennå
Studietype
Observasjonsmessig
Registrering (Forventet)
500
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Chul Woo Ahn, MD
- Telefonnummer: 82-02-2019-3339
- E-post: acw@yuhs.ac
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 100 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients with either type 2 diabetes or impaired glucose toloerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
Beskrivelse
Inclusion Criteria:
- Patients older than 20 years old who has visited Gangnam severance hospital since January 2007.
- Patients with either diabetes or impaired glucose tolerance
- Patients with at least 6 months of follow-up period
Exclusion Criteria:
1. Patients with gestational diabetes, any active stage of cancer and severe disability
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Diabetes and Impaired glucose Tolerance (G-CREDIT)
Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Past medical history
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Smoking, alcohol history
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Sleep, exercise, daily activity check
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Diet
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Reproductive status (Women only)
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Socioeconomic status
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Anthropometric measurements : Height, weight, waist circumference, pulse rate, blood pressure
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
SMA, TG, HDL, LDLM apoA, apoB
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
PC2hrs, HbA1C, Insulin, C-peptide (AC, PC2hr), hs-CRP
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Urine protein, albumin, creatinine
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
EKG, Neurometer, Chest PA, Abdominal sonography
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Fundus photography, fat computed tomography
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
HOMA-IR, HOMA-β
Tidsramme: an expected average of 12 weeks
|
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
|
an expected average of 12 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2007
Primær fullføring (Forventet)
1. februar 2026
Studiet fullført (Forventet)
1. februar 2026
Datoer for studieregistrering
Først innsendt
27. mars 2016
Først innsendt som oppfylte QC-kriteriene
27. mars 2016
Først lagt ut (Anslag)
1. april 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
18. april 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. april 2016
Sist bekreftet
1. april 2016
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 3-2010-0195
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
This study has a plan to share data
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkjentHER-2 genamplifikasjon | HER-2 Protein Overekspresjon
-
The University of Tennessee, KnoxvilleFullførtMattelærere (2.–8. klasse) | Mattestudenter (2.–8. klasse)Forente stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkjentSolid svulst | HER-2 genamplifikasjon | HER2 genmutasjon | HER-2 Protein OverekspresjonKina
-
PowderMedFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Aktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Aktiv, ikke rekrutterende
-
Arcturus Therapeutics, Inc.Avsluttet
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsFullført